<DOC>
	<DOCNO>NCT00378690</DOCNO>
	<brief_summary>Phase IIIb , Open-label , randomize , control multi-centre study . Induction therapy phase 6 month subject receive 2 ELIGARD depot injection . Those subject hormone responsive prostate cancer randomize receive either intermittent continuous ELIGARD treatment 36 month . Following treatment period , subject enter long-term follow-up period 48 month .</brief_summary>
	<brief_title>A Phase IIIb Study Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>At study entry ( visit 1 ) : Written inform consent Male subject age &gt; =18 &lt; 80 year old Locally advanced ( stage T3 T4 ) prostate cancer Relapsing prostate cancer follow radical prostatectomy , Relapsing prostate cancer follow radiotherapy Gleason score &gt; =6 ECOG performance status 02 . Life expectancy least 5 year At randomization ( visit 4 ) : Two successive decrease serum PSA level &lt; =1 ng/ml At study entry ( visit 1 ) : Any suspected second primary tumor Evidence metastatic disease Other malignancy within last 5 year except Acute spinal cord compression , uni bilateral ureteric obstruction Any concurrent biological response modifier therapy Concurrent chemotherapy Less 1 year since prior neoadjuvant adjuvant hormonal therapy Less 6 month since prior 5alpha reductase inhibitor treatment Other concurrent hormonal therapy Any concurrent radiotherapy Testosterone screen &lt; = 1.7 mM 50 ng/dL Clinically significant elevation serum creatinine liver enzymes Hypersensitivity GnRH GnRH analogues leuprorelin acetate Hypersensitivity CASODEXÃ¢ 50 mg .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Specific Antigen</keyword>
</DOC>